Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background And Aims: Conversion therapy downstages tumors and renders patients with unresectable hepatocellular carcinoma (HCC) eligible for radical resection. This study aimed to evaluate the efficacy and safety of tislelizumab plus lenvatinib and hepatic artery infusion chemotherapy with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4-HAIC) as a first-line conversion therapy.
Methods: Clinical data from HCC patients who were treated with the triple therapy between April 2021 and April 2022 were retrospectively analyzed. The primary outcome included objective response rate (ORR), disease control rate (DCR), conversion resection rate (CRR), and treatment-related adverse events (TRAEs).
Results: A total of 18 patients completed conversion therapy assessment, which ended on March 27, 2023. The patients had a median age of 55.5 (37-72) years, and 94.4% were male. According to mRECIST, tumor shrinkage was observed in all patients, with an ORR of 94.4% (17/18), a DCR of 94.4% (17/18), and a median time to response of 1.4 (0.7-3.0) months. Successful conversion was observed in 61.1% (11/18) of patients (mRECIST). The CRR and pathological complete response were 38.9% (7/18) and 57.1% (4/7), respectively. The median progression-free survival (PFS) was 17.8 months, while median overall survival was not reached. The 6- and 9-month PFS rates were 83.3% and 66.7%, respectively. The most common TRAE (16/18 patients, 88.9%) was an increase in aspartate aminotransferase levels.
Conclusion: Tislelizumab combined with lenvatinib and FOLFOX4-HAIC achieved a high conversion rate and acceptable toxicity in patients with unresectable HCC, suggesting that this combination may represent a new conversion strategy for this population.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12212711 | PMC |
| http://dx.doi.org/10.1016/j.iliver.2023.08.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biomimetic Multinuclear Nickel-Polyphenol Artificial Enzyme with Synergistic Catalytic Centers for Broad-Spectrum RONS Scavenging: A Therapeutic Strategy against LPS-Induced Septic Cardiomyopathy.
Mol Pharm
September 2025
Affiliated Hospital of Shandong Second Medical University, Shandong Second Medical University, Weifang 261053, Shandong, P. R. China.
Myocardial injury constitutes a life-threatening complication of sepsis, driven by synergistic oxidative-inflammatory pathology involving dysregulated production of reactive oxygen species (ROS), reactive nitrogen species (RNS), and proinflammatory cytokines. This pathophysiological cascade remarkably elevates morbidity and mortality rates in septic patients, emerging as a key contributor to poor clinical outcomes. Despite its clinical significance, no clinically validated therapeutics currently exist for managing septic cardiomyopathy.
View Article and Find Full Text PDFDiscovery of Novel Multifunctional Paramagnetic Platforms: Cell Sorting and Theranostics Based on Active Molecules of Vascular Normalization.
Anal Chem
September 2025
School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, China.
The novel multifunctional theranostic platform is highly regarded in clinical applications, often achieving desired outcomes in real-time tumor monitoring and personalized treatment. Paramagnetic micron/nanoparticles often exhibit strong magnetic resonance imaging (MRI) contrast and high photothermal conversion efficiency, making them a powerful alternative to small-molecule contrast agents for MRI diagnostics. Additionally, these particles possess high modifiability, making them highly promising for clinical use in dual-modal imaging-guided personalized tumor therapy.
View Article and Find Full Text PDFLineage Switch of Adult B-Cell Acute Lymphoblastic Leukaemia to Acute Myeloid Leukaemia Following B-Cell-Directed Therapy.
Eur J Case Rep Intern Med
August 2025
Division of Hematology and Oncology, UNM Comprehensive Cancer Center, Albuquerque, USA.
Background: Blinatumomab and inotuzumab ozogamicin (InO) are B-cell targeted agents used in the frontline and relapsed/refractory treatment of B-cell acute lymphoblastic leukaemia (B-ALL). Blinatumomab, a bispecific T-cell engager that targets CD19 and CD3, and InO, an antibody-drug conjugate targeting CD22, have both shown efficacy. However, recent reports have noted lineage conversion as a complication when these agents are used individually or sequentially.
View Article and Find Full Text PDFDose-dependent modulation of hepatic cytochrome P450 enzymes by tenvermectin: implications for medication safety and combination therapy.
Front Vet Sci
August 2025
College of Food Science, Guangdong Provincial Key Laboratory of Food Quality and Safety, South China Agricultural University, Guangzhou, China.
Introduction: Tenvermectin (TVM) is a novel avermectin-class drug that has attracted attention for its superior antiparasitic potency, low toxicity, and broad-spectrum activity. However, uncertainty about its interaction with cytochrome P450 enzymes (CYPs) has raised concerns about potential therapeutic failure, increased risk of toxicity, dangerous drug combinations, and prolonged discontinuation periods.
Method: To address these critical safety concerns, we conducted a systematic comparative study using a highly selective and quantitatively accurate substrate conversion assay to assess and compare the effects of TVM and ivermectin (IVM) on the activities of key CYPs (CYP1A1/2, 2B1, 2C6, 2D2, and 3A1/2).
Ferroptosis-Enhanced Radiopharmaceutical Therapy via a Manganese-Based Nanoplatform.
Mol Pharm
September 2025
Department of Nuclear Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.
Radiopharmaceutical therapy (RPT) is a therapeutic strategy that delivers radionuclides in a targeted manner to achieve precise radiation-induced killing of tumor cells. While RPT primarily induces tumor cell death through apoptosis, resistance to apoptosis has been identified as a key mechanism underlying the radioresistance. Therefore, integrating nonapoptotic cell death pathways with RPT offers a promising strategy to enhance its therapeutic efficacy.
View Article and Find Full Text PDF